Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
Anna Luise Grab(German Cancer Research Center), Marc S. Raab(Unknown), Philipp Reichert(Heidelberg University), Stefanie Gryzik(Heidelberg University), Calin Manta(Heidelberg University), Debarati Shome, Helgi van de Velde(Sanofi (Belgium)), Niels Weinhold(German Cancer Research Center), Anja Baumann(University of Vienna), Kamlesh Bisht, Irene Sarkar, Peter Kim(Sanofi (United States)), Lukas John(University of Hohenheim), Hongfang Wang(Memorial Sloan Kettering Cancer Center), Rogier M. Reijmers(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 18
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
|Blood|2018|492
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
|Leukemia|2018|452
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
|Nature Communications|2017|418
NOTCH1–RBPJ complexes drive target gene expression through dynamic interactions with superenhancers
|Proceedings of the National Academy of Sciences|2013|266